Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by investment analysts at Piper Jaffray Companies in a research report issued on Friday. They currently have a $14.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target suggests a potential upside of 37.39% from the stock’s current price.

COLL has been the subject of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, May 31st. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Janney Montgomery Scott reiterated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $21.33.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 10.19 on Friday. The firm’s 50-day moving average is $10.78 and its 200 day moving average is $11.20. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $20.55. The company’s market capitalization is $301.28 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Equities analysts expect that Collegium Pharmaceutical will post ($3.00) EPS for the current year.

WARNING: “Collegium Pharmaceutical, Inc. (COLL) Rating Reiterated by Piper Jaffray Companies” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-rating-reiterated-by-piper-jaffray-companies/1547642.html.

Several hedge funds and other institutional investors have recently bought and sold shares of COLL. Teachers Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 18.1% during the 4th quarter. Teachers Advisors LLC now owns 25,437 shares of the specialty pharmaceutical company’s stock valued at $396,000 after acquiring an additional 3,892 shares during the last quarter. Macquarie Group Ltd. bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $127,000. Nationwide Fund Advisors boosted its position in shares of Collegium Pharmaceutical by 16.4% during the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 1,422 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Collegium Pharmaceutical by 404.1% during the 1st quarter. Wells Fargo & Company MN now owns 86,776 shares of the specialty pharmaceutical company’s stock valued at $873,000 after acquiring an additional 69,563 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Collegium Pharmaceutical by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after acquiring an additional 3,775 shares during the last quarter. Hedge funds and other institutional investors own 83.13% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.